Eyp-1901
Payments companies reported to CMS as associated with Eyp-1901. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Eyp-1901, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Eyp-1901
These are the largest totals companies reported as associated with Eyp-1901. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| David Guyer | New York, NY | Ophthalmology | $145,938.59 |
| Carl Regillo | Plymouth Meeting, PA | Ophthalmology | $131,745.06 |
| Charles Wykoff | Bellaire, TX | Ophthalmology | $123,428.86 |
| David Boyer | Los Angeles, CA | Ophthalmology | $105,392.46 |
| Rishi Singh | Boston, MA | Ophthalmology | $43,322.42 |
| Sumit Sharma | Cleveland, OH | Retina Specialist | $26,022.54 |
| David Eichenbaum | St Petersburg, FL | Ophthalmology | $23,385.30 |
| Roger Goldberg | Walnut Creek, CA | Retina Specialist | $19,965.11 |
| Christina Weng | Houston, TX | Ophthalmology | $16,881.79 |
| Allen Ho | Plymouth Meeting, PA | Ophthalmology | $15,163.98 |
Prescribed Eyp-1901?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.